206 related articles for article (PubMed ID: 17824795)
1. Imatinib in the management of multiple gastrointestinal stromal tumors associated with a germline KIT K642E mutation.
Graham J; Debiec-Rychter M; Corless CL; Reid R; Davidson R; White JD
Arch Pathol Lab Med; 2007 Sep; 131(9):1393-6. PubMed ID: 17824795
[TBL] [Abstract][Full Text] [Related]
2. Rectal gastrointestinal stromal tumors associated with a novel germline KIT mutation.
Woźniak A; Rutkowski P; Sciot R; Ruka W; Michej W; Debiec-Rychter M
Int J Cancer; 2008 May; 122(9):2160-4. PubMed ID: 18183595
[TBL] [Abstract][Full Text] [Related]
3. Diagnosis, prognosis and treatment of patients with gastrointestinal stromal tumour (GIST) and germline mutation of KIT exon 13.
Bachet JB; Landi B; Laurent-Puig P; Italiano A; Le Cesne A; Lévy P; Safar V; Duffaud F; Blay JY; Emile JF
Eur J Cancer; 2013 Jul; 49(11):2531-41. PubMed ID: 23648119
[TBL] [Abstract][Full Text] [Related]
4. Tyrosine-kinase mutations in c-KIT and PDGFR-alpha genes of imatinib naïve adult patients with gastrointestinal stromal tumours (GISTs) of the stomach and small intestine: relation to tumour-biological risk-profile and long-term outcome.
Søreide K; Sandvik OM; Søreide JA; Gudlaugsson E; Mangseth K; Haugland HK
Clin Transl Oncol; 2012 Aug; 14(8):619-29. PubMed ID: 22855146
[TBL] [Abstract][Full Text] [Related]
5. KIT and PDGFRA mutations in gastrointestinal stromal tumors (GISTs).
Lasota J; Miettinen M
Semin Diagn Pathol; 2006 May; 23(2):91-102. PubMed ID: 17193822
[TBL] [Abstract][Full Text] [Related]
6. Remarkable effects of imatinib in a family with young onset gastrointestinal stromal tumors and cutaneous hyperpigmentation associated with a germline KIT-Trp557Arg mutation: case report and literature overview.
Farag S; van der Kolk LE; van Boven HH; van Akkooi ACJ; Beets GL; Wilmink JW; Steeghs N
Fam Cancer; 2018 Apr; 17(2):247-253. PubMed ID: 28710566
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants.
Debiec-Rychter M; Cools J; Dumez H; Sciot R; Stul M; Mentens N; Vranckx H; Wasag B; Prenen H; Roesel J; Hagemeijer A; Van Oosterom A; Marynen P
Gastroenterology; 2005 Feb; 128(2):270-9. PubMed ID: 15685537
[TBL] [Abstract][Full Text] [Related]
8. Familial and multiple gastrointestinal stromal tumors with fair response to a half-dose of imatinib.
Bamba S; Hirota S; Inatomi O; Ban H; Nishimura T; Shioya M; Imaeda H; Nishida A; Sasaki M; Murata S; Andoh A
Intern Med; 2015; 54(7):759-64. PubMed ID: 25832938
[TBL] [Abstract][Full Text] [Related]
9. Molecular characterization of an Italian series of sporadic GISTs.
Origone P; Gargiulo S; Mastracci L; Ballestrero A; Battistuzzi L; Casella C; Comandini D; Cusano R; Dei Tos AP; Fiocca R; Garuti A; Ghiorzo P; Martinuzzi C; Toffolatti L; ; Bianchi Scarrà G
Gastric Cancer; 2013 Oct; 16(4):596-601. PubMed ID: 23291969
[TBL] [Abstract][Full Text] [Related]
10. Molecular analysis of secondary kinase mutations in imatinib-resistant gastrointestinal stromal tumors.
Lim KH; Huang MJ; Chen LT; Wang TE; Liu CL; Chang CS; Liu MC; Hsieh RK; Tzen CY
Med Oncol; 2008; 25(2):207-13. PubMed ID: 18488160
[TBL] [Abstract][Full Text] [Related]
11. Treatment of patients with advanced gastrointestinal stromal tumor of small bowel: implications of imatinib mesylate.
Yeh CN; Chen TW; Wu TJ; Hsueh S; Jan YY
World J Gastroenterol; 2006 Jun; 12(23):3760-5. PubMed ID: 16773696
[TBL] [Abstract][Full Text] [Related]
12. [The importance of mutational status in prognosis and therapy of GIST].
Comandone A; Boglione A
Recenti Prog Med; 2015 Jan; 106(1):17-22. PubMed ID: 25621775
[TBL] [Abstract][Full Text] [Related]
13. The role of KIT in the management of patients with gastrointestinal stromal tumors.
Hornick JL; Fletcher CD
Hum Pathol; 2007 May; 38(5):679-87. PubMed ID: 17437861
[TBL] [Abstract][Full Text] [Related]
14. Pathology of gastrointestinal stromal tumors.
Hirota S; Isozaki K
Pathol Int; 2006 Jan; 56(1):1-9. PubMed ID: 16398673
[TBL] [Abstract][Full Text] [Related]
15. Correlation of imatinib resistance with the mutational status of KIT and PDGFRA genes in gastrointestinal stromal tumors: a meta-analysis.
Lee JH; Kim Y; Choi JW; Kim YS
J Gastrointestin Liver Dis; 2013 Dec; 22(4):413-8. PubMed ID: 24369323
[TBL] [Abstract][Full Text] [Related]
16. Secondary resistance to imatinib mesylate in a patient with unresectable duodenal GIST without mutations in exons 9, 11, 13, or 17 of the c-kit protooncogene.
Yamaguchi M; Matsumoto T; Tate G; Higuchi T
J Gastroenterol; 2004 Sep; 39(9):904-5. PubMed ID: 15565413
[No Abstract] [Full Text] [Related]
17. High-resolution melting analysis is a sensitive diagnostic tool to detect imatinib-resistant and imatinib-sensitive PDGFRA exon 18 mutations in gastrointestinal stromal tumors.
Künstlinger H; Binot E; Merkelbach-Bruse S; Huss S; Wardelmann E; Buettner R; Schildhaus HU
Hum Pathol; 2014 Mar; 45(3):573-82. PubMed ID: 24444465
[TBL] [Abstract][Full Text] [Related]
18. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours.
Debiec-Rychter M; Sciot R; Le Cesne A; Schlemmer M; Hohenberger P; van Oosterom AT; Blay JY; Leyvraz S; Stul M; Casali PG; Zalcberg J; Verweij J; Van Glabbeke M; Hagemeijer A; Judson I; ; ;
Eur J Cancer; 2006 May; 42(8):1093-103. PubMed ID: 16624552
[TBL] [Abstract][Full Text] [Related]
19. Practical role of mutation analysis for imatinib treatment in patients with advanced gastrointestinal stromal tumors: a meta-analysis.
Zhi X; Zhou X; Wang W; Xu Z
PLoS One; 2013; 8(11):e79275. PubMed ID: 24223922
[TBL] [Abstract][Full Text] [Related]
20. Molecular alterations and expression of succinate dehydrogenase complex in wild-type KIT/PDGFRA/BRAF gastrointestinal stromal tumors.
Celestino R; Lima J; Faustino A; Vinagre J; Máximo V; Gouveia A; Soares P; Lopes JM
Eur J Hum Genet; 2013 May; 21(5):503-10. PubMed ID: 22948025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
